Immunotech Biopharm Ltd
HKEX:6978
Immunotech Biopharm Ltd
HKEX:6978
Price:
3.63
HKD
-1.09%
Market Closed
Market Cap:
HK$2.2B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Immunotech Biopharm Ltd
HKEX:6978
|
CN |
|
W
|
Wuhan Yangtze Communication Industry Group Co Ltd
SSE:600345
|
CN |
Income Statement
Earnings Waterfall
Immunotech Biopharm Ltd
Immunotech Biopharm Ltd
Income Statement
Immunotech Biopharm Ltd
Immunotech Biopharm Ltd
Currency: CNY
| Dec-2020 | Jun-2021 | Dec-2021 | Jun-2022 | Dec-2022 | Jun-2023 | Dec-2023 | Jun-2024 | Dec-2024 | Jun-2025 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||
| Interest Expense |
2
|
0
|
4
|
0
|
6
|
0
|
9
|
0
|
7
|
0
|
0
|
|
| Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
| Operating Income | ||||||||||||
| Operating Expenses |
(345)
|
(371)
|
(334)
|
(331)
|
(280)
|
(242)
|
(240)
|
(206)
|
(138)
|
(192)
|
(223)
|
|
| Selling, General & Administrative |
(69)
|
(84)
|
(104)
|
(108)
|
(98)
|
(76)
|
(53)
|
(51)
|
(45)
|
(41)
|
(41)
|
|
| Research & Development |
(267)
|
(278)
|
(226)
|
(212)
|
(149)
|
(116)
|
(135)
|
(150)
|
(107)
|
(84)
|
(88)
|
|
| Depreciation & Amortization |
(11)
|
(13)
|
(14)
|
(21)
|
(27)
|
(34)
|
(42)
|
(45)
|
(47)
|
(47)
|
(45)
|
|
| Other Operating Expenses |
2
|
4
|
11
|
11
|
(6)
|
(15)
|
(9)
|
40
|
60
|
(20)
|
(49)
|
|
| Operating Income |
(345)
N/A
|
(371)
-8%
|
(334)
+10%
|
(331)
+1%
|
(280)
+16%
|
(242)
+13%
|
(240)
+1%
|
(206)
+14%
|
(138)
+33%
|
(192)
-38%
|
(223)
-16%
|
|
| Pre-Tax Income | ||||||||||||
| Interest Income Expense |
(56)
|
(40)
|
(21)
|
(18)
|
(27)
|
(42)
|
(96)
|
(84)
|
(26)
|
(29)
|
(7)
|
|
| Non-Reccuring Items |
(38)
|
(1)
|
1
|
(0)
|
(1)
|
(1)
|
0
|
(19)
|
(20)
|
(1)
|
(0)
|
|
| Total Other Income |
(0)
|
(1)
|
(0)
|
(0)
|
(14)
|
(13)
|
(1)
|
(1)
|
(2)
|
(2)
|
(1)
|
|
| Pre-Tax Income |
(439)
N/A
|
(413)
+6%
|
(355)
+14%
|
(349)
+2%
|
(321)
+8%
|
(297)
+7%
|
(335)
-13%
|
(309)
+8%
|
(186)
+40%
|
(223)
-20%
|
(231)
-4%
|
|
| Net Income | ||||||||||||
| Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(1)
|
(1)
|
0
|
|
| Income from Continuing Operations |
(439)
|
(413)
|
(355)
|
(349)
|
(321)
|
(297)
|
(335)
|
(309)
|
(187)
|
(224)
|
(231)
|
|
| Income to Minority Interest |
0
|
0
|
0
|
2
|
3
|
2
|
1
|
0
|
0
|
0
|
0
|
|
| Net Income (Common) |
(439)
N/A
|
(412)
+6%
|
(354)
+14%
|
(347)
+2%
|
(318)
+8%
|
(296)
+7%
|
(335)
-13%
|
(309)
+8%
|
(187)
+40%
|
(224)
-20%
|
(231)
-3%
|
|
| EPS (Diluted) |
-0.99
N/A
|
-0.8
+19%
|
-0.69
+14%
|
-0.67
+3%
|
-0.57
+15%
|
-0.58
-2%
|
-0.6
-3%
|
-0.55
+8%
|
-0.33
+40%
|
-0.4
-21%
|
-0.42
-5%
|
|
Switch to:
Switch to:
See Also
Discover More
